Atrial fibrillation: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
|||
| (39 intermediate revisions by 14 users not shown) | |||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{| | |||
| | {| class="infobox" style="float:right;" | ||
|- | |||
|[[File:Siren.gif|30px|link=Atrial fibrillation resident survival guide]]||<br>||<br> | |||
|[[Atrial fibrillation resident survival guide|'''Resident'''<br>'''Survival'''<br>'''Guide''']] | |||
|} | |||
{| class="infobox" style="float:right;" | |||
|- | |||
|[[Image:Heart conduct sinus.gif|150px|]]<BR><small>'''Sinus rhythm'''</small> | |||
|} | |||
{| class="infobox" style="float:right;" | |||
|- | |- | ||
| | |[[Image:Heart conduct atrialfib.gif|150px]]<BR><small>'''Atrial fibrillation'''</small> | ||
|} | |} | ||
{{Atrial fibrillation}} | {{Atrial fibrillation}} | ||
{{Patient}} | |||
{{CMG}} | {{CMG}} {{AE}} {{Anahita}} {{Laith}} | ||
{{SK}} AF; afib | {{SK}} AF; afib; lone fibrillator | ||
==[[Atrial fibrillation overview|Overview]]== | ==[[Atrial fibrillation overview|Overview]]== | ||
==[[Atrial fibrillation historical perspective|Historical Perspective]]== | |||
==[[Atrial fibrillation classification|Classification]]== | ==[[Atrial fibrillation classification|Classification]]== | ||
| Line 31: | Line 40: | ||
==Special Groups== | ==Special Groups== | ||
[[Postoperative atrial fibrillation|Postoperative AF]] | [[Atrial fibrillation acute myocardial infarction|Acute Myocardial Infarction]] | [[Atrial fibrillation Wolff-Parkinson-White preexcitation syndromes|Wolff-Parkinson-White Preexcitation Syndromes]] | [[Atrial fibrillation hypertrophic cardiomyopathy|Hypertrophic Cardiomyopathy]] | [[Atrial fibrillation hyperthyroidism|Hyperthyroidism]] | [[Atrial fibrillation pulmonary diseases|Pulmonary Diseases]] | [[Atrial fibrillation pregnancy|Pregnancy]] | [[Postoperative atrial fibrillation|Postoperative AF]] | [[Atrial fibrillation acute myocardial infarction|Acute Myocardial Infarction]] | [[Atrial fibrillation Wolff-Parkinson-White preexcitation syndromes|Wolff-Parkinson-White Preexcitation Syndromes]] | [[Atrial fibrillation hypertrophic cardiomyopathy|Hypertrophic Cardiomyopathy]] | [[Atrial fibrillation hyperthyroidism|Hyperthyroidism]] | [[Atrial fibrillation pulmonary diseases|Pulmonary Diseases]] | [[Atrial fibrillation pregnancy|Pregnancy]] | [[Atrial fibrillation medical therapy in patients presenting with ACS and/or PCI or valve intervention|Patients Presenting with ACS and/or PCI or Valve Intervention]] | ||
==Diagnosis== | ==Diagnosis== | ||
| Line 37: | Line 46: | ||
==[[Atrial fibrillation overview of treatment|Treatment]]== | ==[[Atrial fibrillation overview of treatment|Treatment]]== | ||
Cardioversion | ===[[Atrial fibrillation rate control|Rate and Rhythm Control]]=== | ||
[[Atrial fibrillation rate control|Rate Control]] | [[Atrial fibrillation maintenance of rate control and sinus rhythm|Maintenance of Sinus Rhythm]] | |||
===Cardioversion=== | |||
[[Atrial fibrillation cardioversion|Overview]] | [[Atrial fibrillation electrical cardioversion|Electrical Cardioversion]] | [[Atrial fibrillation pharmacological cardioversion|Pharmacological Cardioversion]] | |||
Anticoagulation | ===Anticoagulation=== | ||
[[Atrial fibrillation anticoagulation|Overview]] | [[Warfarin]] | [[Dabigatran#Converting from or to Warfarin|Converting from or to Warfarin]] | [[Dabigatran#Converting from or to Parenteral Anticoagulants|Converting from or to Parenteral Anticoagulants]] | [[Dabigatran]] | |||
===Dabigatran=== | |||
[[dabigatran#Dosing|Dosing]] | [[Dabigatran#Surgery and Interventions|Discontinuation for Surgery and Interventions]] | [[Dabigatran#WARNINGS AND PRECAUTIONS| Warnings and Precautions]] | [[Dabigatran#Adverse Reactions|Adverse Reactions]] | [[Dabigatran#Use in Specific Populations|Use in Specific Populations Such as Pregnancy]] | [[Dabigatran#Overdosage|Overdosage]] | [[Clinical Pharmacology of Dabigatran|Clinical Pharmacology]] | [[FDA Review of Data From the RE-LY Trial on September 20th, 2010|FDA Review of the RE-LY Data]] | [[A comparison of the RE-LY and Rocket AF Trials ]] | [[Estimates of Cost Per Year of Life Saved for Dabigatran]] | |||
===Ablation=== | |||
[[Atrial fibrillation catheter ablation|Catheter Ablation]] | [[AV nodal ablation|AV Nodal Ablation]] | [[Atrial fibrillation surgical ablation|Surgical Ablation]] | |||
[[Atrial fibrillation | ===Surgery=== | ||
[[Atrial fibrillation surgical treatment|Maze Open Heart Surgery]] | |||
[[Atrial fibrillation | ===[[Atrial fibrillation secondary prevention|Secondary Prevention]]=== | ||
===[[Atrial fibrillation supportive trial data|Supportive Trial Data]]=== | |||
===[[Atrial fibrillation cost-effectiveness of therapy|Cost-effectiveness of Therapy]]=== | |||
==Case Studies== | ==Case Studies== | ||
| Line 54: | Line 73: | ||
==Related Chapters== | ==Related Chapters== | ||
* [[Atrial flutter]] | |||
* [[Ashman phenomenon]] | *[[Atrial flutter]] | ||
* [[The Living Guidelines: Diagnosis and Management of Atrial Fibrillation | The AF Living Guidelines: Vote on current recommendations and suggest revisions to the guidelines]] | *[[Ashman phenomenon]] | ||
*[[The Living Guidelines: Diagnosis and Management of Atrial Fibrillation | The AF Living Guidelines: Vote on current recommendations and suggest revisions to the guidelines]] | |||
{{Electrocardiography}} | {{Electrocardiography}} | ||
{{Circulatory system pathology}} | {{Circulatory system pathology}} | ||
{{WikiDoc Help Menu}} | {{WikiDoc Help Menu}} | ||
{{WikiDoc Sources}} | {{WikiDoc Sources}} | ||
[[CME Category::Cardiology]] | |||
[[Category:Arrhythmia]] | |||
[[Category:Cardiology]] | |||
[[Category:Electrophysiology]] | [[Category:Electrophysiology]] | ||
[[Category:Emergency medicine]] | [[Category:Emergency medicine]] | ||
[[Category:Up-To-Date]] | |||
[[Category:Up-To-Date Cardiology]] | |||
Latest revision as of 03:26, 14 December 2022
 |
Resident Survival Guide |
 Sinus rhythm |
 Atrial fibrillation |
|
Atrial Fibrillation Microchapters | |
|
Special Groups | |
|---|---|
|
Diagnosis | |
|
Treatment | |
|
Cardioversion | |
|
Anticoagulation | |
|
Surgery | |
|
Case Studies | |
|
Atrial fibrillation On the Web | |
For patient information, click here. Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Anahita Deylamsalehi, M.D.[2] Laith Adnan Allaham, M.D.[3]
Synonyms and keywords: AF; afib; lone fibrillator
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Atrial Fibrillation from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Special Groups
Postoperative AF | Acute Myocardial Infarction | Wolff-Parkinson-White Preexcitation Syndromes | Hypertrophic Cardiomyopathy | Hyperthyroidism | Pulmonary Diseases | Pregnancy | Patients Presenting with ACS and/or PCI or Valve Intervention
Diagnosis
History and Symptoms | Physical Examination | Laboratory Findings | Electrocardiogram | EKG Examples | Afib with LBBB EKG Examples | Chest X Ray | Echocardiography | Holter Monitoring and Exercise Stress Testing | Cardiac MRI
Treatment
Rate and Rhythm Control
Rate Control | Maintenance of Sinus Rhythm
Cardioversion
Overview | Electrical Cardioversion | Pharmacological Cardioversion
Anticoagulation
Overview | Warfarin | Converting from or to Warfarin | Converting from or to Parenteral Anticoagulants | Dabigatran
Dabigatran
Dosing | Discontinuation for Surgery and Interventions | Warnings and Precautions | Adverse Reactions | Use in Specific Populations Such as Pregnancy | Overdosage | Clinical Pharmacology | FDA Review of the RE-LY Data | A comparison of the RE-LY and Rocket AF Trials | Estimates of Cost Per Year of Life Saved for Dabigatran
Ablation
Catheter Ablation | AV Nodal Ablation | Surgical Ablation